Serum Institute launches HPV-Cancer public awareness campaign

The “Conquer HPV & Cancer Conclave 2025” was launched today in Coimbatoreas part of a nationwide public health initiative led by the Serum Institute of India (SII).
India continues to face a significant burden of HPV-related diseases, particularly cervical cancer, which remains the second most common cancer among women in the country. According to the ICO/IARC Information Centre on HPV and Cancer (2023), India reports over 1.23 lakh new cervical cancer cases and more than 77,000 related deaths annually. Apart from this up to 90% of anal cancers & 63% of penile cancers are associated with HPV.
At the Coimbatore event, a panel of medical specialists engaged in an in-depth discussion about the public health implications of HPV. The panel included:
Dr. T V Chitra Bhat – Professor- Unit Head in PSG IMS&R. HPV Faculty for training of IMA. Member, Master Trainer In FOGSI & IAP HPV Vaccination Project 2023–2024
Dr. K. Aarathy – MD & Lead Consultant- MANU Hospital, Coimbatore. Center-in-charge, CIMAR, Coimbatore. Joint Secretary- TN Indian Fertility Society. Vice President- COGS
Dr. P. Senthil Kumar – Senior Assistant Professor, Neonatology, Medical College Hospital, Coimbatore. Head- Newborn Unit, Hindustan Hospitals, Coimbatore. Regional Nodal Officer for SNCU's TN – West
Dr. A. Jayavardhana– Professor and Head- PSG Institute of Medical Sciences and Research, Coimbatore. Executive Board Member, IAP, TNSC Chapter
Dr. Jayashree N. – Gynecologic Oncologist, Associate Professor, Cancer Institute (WIA) Adyar, Chennai. EC Member, AOGIN India (2024–2026), EC Member, AGOI Pondy, TN Chapter (2024–2026)
The session was moderated by Dr. Nandhini Kumaran – Consultant- Pediatrician, Masonic Medical Centre for Children & Sri Ramakrishna Hospital, Coimbatore. Chairperson- National IAP Conference – Pedicon (2019). 
The speakers emphasized that HPV is not limited to cervical cancer alone. It is also associated with cancers of the vulva, vagina, anus, penis, and oropharynx, affecting both men and women. With peak HPV infection occurring between ages 15 to 25, early awareness and timely preventive action are essential. With an affordable HPV vaccine now available, it has become still more easier to protect every individual from HPV associated cancers.
“Through these conclaves held across the country, we aim to increase understanding of Human Papillomavirus (HPV) and its link to cervical and other cancers,” said Parag Deshmukh, Executive Director, Serum Institute of India.